Sulfonylurea receptor

Sulfonylurea receptor (SUR) is a type of protein that plays a crucial role in the regulation of insulin secretion by pancreatic beta cells. These receptors are integral parts of the ATP-sensitive potassium (K_ATP) channels, which are essential for maintaining glucose homeostasis in the body. The interaction between sulfonylureas, a class of antidiabetic drugs, and these receptors facilitates the closure of K_ATP channels, leading to the depolarization of the beta cell membrane and subsequent insulin release.

Structure and Function

The sulfonylurea receptor is a complex protein that belongs to the ATP-binding cassette (ABC) transporter family. It is encoded by two genes, ABCC8 (SUR1) and ABCC9 (SUR2), which give rise to different isoforms of the receptor. SUR1 is predominantly found in pancreatic beta cells, while SUR2 variants are expressed in cardiac and skeletal muscle tissues.

The K_ATP channel is a hetero-octameric complex composed of four Kir6.x potassium channel subunits and four sulfonylurea receptor subunits. The interaction between these subunits is critical for the channel's response to metabolic changes. When intracellular ATP levels are high, indicating a high glucose concentration, the K_ATP channels close, causing cell membrane depolarization. This depolarization opens voltage-dependent calcium channels, leading to an influx of calcium ions and triggering insulin secretion.

Clinical Significance

Sulfonylurea receptors are the target of sulfonylurea drugs, which are used in the treatment of Type 2 diabetes. These drugs bind to the receptor, leading to the inhibition of the K_ATP channel, insulin secretion, and a decrease in blood glucose levels. However, the effectiveness of sulfonylureas can diminish over time, and their use is associated with the risk of hypoglycemia and weight gain.

Mutations in the genes encoding the sulfonylurea receptor can lead to various forms of Congenital Hyperinsulinism (CHI), a condition characterized by excessive insulin secretion. These mutations can either increase the activity of the K_ATP channel, leading to constant insulin release, or reduce the sensitivity of the receptor to ATP, preventing the channel from closing in response to high glucose levels.

Pharmacology

The pharmacological manipulation of sulfonylurea receptors offers a therapeutic avenue for managing Type 2 diabetes. First-generation sulfonylureas, such as tolbutamide and chlorpropamide, have largely been replaced by second-generation drugs like glimepiride, glibenclamide (also known as glyburide), and glipizide, which are more potent and have a shorter duration of action.

Research is ongoing to develop drugs that selectively target different isoforms of the sulfonylurea receptor, aiming to minimize side effects and improve the efficacy of treatment. Additionally, understanding the genetic variations in the SUR genes may help personalize diabetes treatment, optimizing drug choice and dosing for individual patients.

See Also

• Insulin
• Diabetes mellitus
• ATP-sensitive potassium channel
• Congenital Hyperinsulinism
• Pharmacogenomics

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian